Trials / Recruiting
RecruitingNCT06321250
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
An Open-label, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Jemincare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JMKX003948 | Subjects will receive JMKX003948 tablets until disease progression |
Timeline
- Start date
- 2024-03-14
- Primary completion
- 2026-05-31
- Completion
- 2027-04-30
- First posted
- 2024-03-20
- Last updated
- 2024-07-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06321250. Inclusion in this directory is not an endorsement.